ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Lai YS et al., 2015. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: A systematic review and geostatistical analysis. Lancet Infect Dis 15: 927–940.
-
2.
WHO , 2022. Schistosomiasis and soil-transmitted helminthiases: Progress report, 2021. Wkly Epidemiol Rec 97: 621–632.
-
3.
WHO , 2022. WHO Guideline on Control and Elimination of Human Schistosomiasis. Geneva, Switzerland: World Health Organization.
-
4.
Doenhoff MJ , Hagan P , Cioli D , Southgate V , Pica-Mattoccia L , Botros S , Coles G , Tchuem Tchuenté LA , Mbaye A , Engels D , 2009. Praziquantel: Its use in the control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitol 136: 1825–1835.
-
5.
Ismail M , Botros S , Metwally A , William S , Farghally A , Tao LF , Day TA , Bennett JL , 1999. Resistance to praziquantel: Direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60: 932–935.
-
6.
Keiser J , Utzinger J , 2012. Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18: 3531–3538.
-
7.
Saeed MEM , Krishna S , Greten HJ , Kremsner PG , Efferth T , 2016. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res 110: 216–226.
-
8.
Utzinger J , Xiao SH , Tanner M , Keiser J , 2007. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8: 105–116.
-
9.
Utzinger J , Keiser J , Shuhua X , Tanner M , Singer BH , 2003. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 47: 1487–1495.
-
10.
Pérez del Villar L , Burguillo FJ , López-Abán J , Muro A , 2012. Systematic review and meta-analysis of artemisinin-based therapies for the treatment and prevention of schistosomiasis. PLoS One 7: e45867.
-
11.
Obonyo CO , Muok EM , Mwinzi PN , 2010. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: An open-label randomised controlled trial. Lancet Infect Dis 10: 603–611.
-
12.
Handzel T , Karanja DM , Addiss DG , Hightower AW , Rosen DH , Colley DG , Andove J , Slutsker L , Secor WE , 2003. Geographic distribution of schistosomiasis and soil-transmitted helminths in Western Kenya: Implications for anthelminthic mass treatment. Am J Trop Med Hyg 69: 318–323.
-
13.
WHO , 2002. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis: WHO Technical Report Series No. 912. Geneva, Switzerland: World Health Organization, 1–57.
-
14.
WHO , 2013. Assessing the Efficacy of Anthelminthic Drugs against Schistosomiasis and Soil-Transmitted Infections. Geneva, Switzerland: World Health Organization.
-
15.
Zwang J , Olliaro PL , 2014. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis – A meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 8: e3286.
-
16.
Stelma FF , Talla I , Sow S , Kongs A , Niang M , Polman K , Deelder AM , Gryseels B , 1995. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53: 167–170.
-
17.
Sissoko MS et al., 2009. Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 4: e6732.
-
18.
Mohamed AA , Mahgoub HM , Magzoub M , Gasim GI , Eldein WN , Ahmed Ael A , Adam I , 2009. Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. Trans R Soc Trop Med Hyg 103: 1062–1064.
-
19.
Ndeffo Mbah ML , Skrip L , Greenhalgh S , Hotez P , Galvani AP , 2014. Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. PLoS Negl Trop Dis 8: e3234.
-
20.
Degarege A , Degarege D , Veledar E , Erko B , Nacher M , Beck-Sague CM , Madhivanan P , 2016. Plasmodium falciparum infection status among children with Schistosoma in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS Negl Trop Dis 10: e0005193.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2441 | 2015 | 48 |
| Full Text Views | 61 | 37 | 6 |
| PDF Downloads | 77 | 42 | 6 |
Efficacy of a Single Oral Dose of Artesunate plus Sulfalene-Pyrimethamine versus Praziquantel in the Treatment of Schistosoma mansoni in Kenyan Children: An Open-Label, Randomized, Exploratory Trial
Erick M. O. Muok
Erick M. O. Muok
Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
Search for other papers by Erick M. O. Muok in
Current site
Google Scholar
PubMed
Search for other papers by Erick M. O. Muok in
Current site
Google Scholar
PubMed
Vincent O. Were
Vincent O. Were
Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
Search for other papers by Vincent O. Were in
Current site
Google Scholar
PubMed
Search for other papers by Vincent O. Were in
Current site
Google Scholar
PubMed
Charles O. Obonyo
Charles O. Obonyo
Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
Search for other papers by Charles O. Obonyo in
Current site
Google Scholar
PubMed
Search for other papers by Charles O. Obonyo in
Current site
Google Scholar
PubMed
ABSTRACT.
Unlike praziquantel, artemisinin derivatives are effective against juvenile schistosome worms. We assessed the efficacy and safety of a single oral dose of artesunate plus sulfalene-pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni. Seventy-three schoolchildren (aged 9–15 years) with confirmed S. mansoni infection in Rarieda, western Kenya, were randomly assigned to receive either a single oral dose of artesunate plus sulfalene-pyrimethamine (n = 39) or a single dose of praziquantel (n = 34). The cure and egg reduction rates at 4 weeks posttreatment were 69.4% (25/36) versus 80.6% (25/31) (P = 0.297) and 99.1% versus 97.5% (P = 0.607) in the artesunate plus sulfalene-pyrimethamine group versus praziquantel group, respectively. Fourteen children developed adverse events, and there were no serious adverse events. A single oral dose of artesunate plus sulfalene-pyrimethamine has efficacy comparable to that of praziquantel in the treatment of S. mansoni, but these results should be confirmed in larger randomized controlled trials.
Author Notes
Financial support: This study was supported by an Internal Research Grant from
Disclosures: The funding agency had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the paper for publication. The authors had full access to all the study data, and the corresponding author had final responsibility for the decision to submit for publication. The study protocol was approved by the Ethics Review Committee based at KEMRI (SSC number 1582). Written informed consent was obtained from parents or legal guardians of potentially eligible children. Oral assent was obtained from children with parasitologically confirmed S. mansoni infection. The trial was conducted according to the Declaration of Helsinki and guidelines on good clinical practice.
Authors’ contributions: C. O. Obonyo initiated the idea and wrote the study protocol. C. O. Obonyo, E. M. O. Muok, and V. O. Were supervised the data collection. C. O. Obonyo and V. O. Were analyzed and interpreted the data. C. O. Obonyo drafted the manuscript. All authors contributed to the writing of the paper and approved the final version.
Data availability: The data sets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.
Authors’ addresses: Erick M. O. Muok, Vincent O. Were, and Charles O. Obonyo, Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya, E-mails: emuok@kemri.go.ke, vincentwere@gmail.com, and cobonyo65@yahoo.com.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Lai YS et al., 2015. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: A systematic review and geostatistical analysis. Lancet Infect Dis 15: 927–940.
-
2.
WHO , 2022. Schistosomiasis and soil-transmitted helminthiases: Progress report, 2021. Wkly Epidemiol Rec 97: 621–632.
-
3.
WHO , 2022. WHO Guideline on Control and Elimination of Human Schistosomiasis. Geneva, Switzerland: World Health Organization.
-
4.
Doenhoff MJ , Hagan P , Cioli D , Southgate V , Pica-Mattoccia L , Botros S , Coles G , Tchuem Tchuenté LA , Mbaye A , Engels D , 2009. Praziquantel: Its use in the control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitol 136: 1825–1835.
-
5.
Ismail M , Botros S , Metwally A , William S , Farghally A , Tao LF , Day TA , Bennett JL , 1999. Resistance to praziquantel: Direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 60: 932–935.
-
6.
Keiser J , Utzinger J , 2012. Antimalarials in the treatment of schistosomiasis. Curr Pharm Des 18: 3531–3538.
-
7.
Saeed MEM , Krishna S , Greten HJ , Kremsner PG , Efferth T , 2016. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol Res 110: 216–226.
-
8.
Utzinger J , Xiao SH , Tanner M , Keiser J , 2007. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 8: 105–116.
-
9.
Utzinger J , Keiser J , Shuhua X , Tanner M , Singer BH , 2003. Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother 47: 1487–1495.
-
10.
Pérez del Villar L , Burguillo FJ , López-Abán J , Muro A , 2012. Systematic review and meta-analysis of artemisinin-based therapies for the treatment and prevention of schistosomiasis. PLoS One 7: e45867.
-
11.
Obonyo CO , Muok EM , Mwinzi PN , 2010. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: An open-label randomised controlled trial. Lancet Infect Dis 10: 603–611.
-
12.
Handzel T , Karanja DM , Addiss DG , Hightower AW , Rosen DH , Colley DG , Andove J , Slutsker L , Secor WE , 2003. Geographic distribution of schistosomiasis and soil-transmitted helminths in Western Kenya: Implications for anthelminthic mass treatment. Am J Trop Med Hyg 69: 318–323.
-
13.
WHO , 2002. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis: WHO Technical Report Series No. 912. Geneva, Switzerland: World Health Organization, 1–57.
-
14.
WHO , 2013. Assessing the Efficacy of Anthelminthic Drugs against Schistosomiasis and Soil-Transmitted Infections. Geneva, Switzerland: World Health Organization.
-
15.
Zwang J , Olliaro PL , 2014. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis – A meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 8: e3286.
-
16.
Stelma FF , Talla I , Sow S , Kongs A , Niang M , Polman K , Deelder AM , Gryseels B , 1995. Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. Am J Trop Med Hyg 53: 167–170.
-
17.
Sissoko MS et al., 2009. Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 4: e6732.
-
18.
Mohamed AA , Mahgoub HM , Magzoub M , Gasim GI , Eldein WN , Ahmed Ael A , Adam I , 2009. Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. Trans R Soc Trop Med Hyg 103: 1062–1064.
-
19.
Ndeffo Mbah ML , Skrip L , Greenhalgh S , Hotez P , Galvani AP , 2014. Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. PLoS Negl Trop Dis 8: e3234.
-
20.
Degarege A , Degarege D , Veledar E , Erko B , Nacher M , Beck-Sague CM , Madhivanan P , 2016. Plasmodium falciparum infection status among children with Schistosoma in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS Negl Trop Dis 10: e0005193.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2441 | 2015 | 48 |
| Full Text Views | 61 | 37 | 6 |
| PDF Downloads | 77 | 42 | 6 |